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Abstract
Background: Good adherence to antiretroviral therapy (ART) is critical for successful HIV treatment. However, some patients
remain virologically suppressed despite suboptimal adherence. We hypothesized that this could result from host genetic
factors influencing drug levels.
Methods: Eligible individuals were Caucasians treated with efavirenz (EFV) and/or boosted lopinavir (LPV/r) with self-
reported poor adherence, defined as missing doses of ART at least weekly for more than 6 months. Participants were
genotyped for single nucleotide polymorphisms (SNPs) in candidate genes previously reported to decrease EFV (rs3745274,
rs35303484, rs35979566 in CYP2B6) and LPV/r clearance (rs4149056 in SLCO1B1, rs6945984 in CYP3A, rs717620 in ABCC2).
Viral suppression was defined as having HIV-1 RNA ,400 copies/ml throughout the study period.
Results: From January 2003 until May 2009, 37 individuals on EFV (28 suppressed and 9 not suppressed) and 69 on LPV/r (38
suppressed and 31 not suppressed) were eligible. The poor adherence period was a median of 32 weeks with 18.9% of EFV
and 20.3% of LPV/r patients reporting missed doses on a daily basis. The tested SNPs were not determinant for viral
suppression. Reporting missing .1 dose/week was associated with a lower probability of viral suppression compared to
missing 1 dose/week (EFV: odds ratio (OR) 0.11, 95% confidence interval (CI): 0.01–0.99; LPV/r: OR 0.29, 95% CI: 0.09–0.94). In
both groups, the probability of remaining suppressed increased with the duration of continuous suppression prior to the
poor adherence period (EFV: OR 3.40, 95% CI: 0.62–18.75; LPV/r: OR 5.65, 95% CI: 1.82–17.56).
Conclusions: The investigated genetic variants did not play a significant role in the sustained viral suppression of individuals
with suboptimal adherence. Risk of failure decreased with longer duration of viral suppression in this population.
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Introduction
High level of adherence to antiretroviral therapy (ART) is
needed to achieve and maintain virological suppression, prevent
drug resistance and improve survival in HIV-infected individuals
[1]. The minimal level of adherence was initially established as
95% of drug intake and was based on data from non-boosted
protease inhibitors (PI) based regimens [1]. More recent studies
have indicated that the optimal level of adherence may differ
according to the antiretroviral class [2,3], and should be greater
than 95% for non-boosted PI or boosted PI and at least 80% for
non-nucleoside reverse transcriptase inhibitors (NNRTI) based
regimens [4].
Although nearly perfect adherence to ART is critical for
successful HIV treatment, some patients remain suppressed
despite poor adherence. The ability to achieve and sustain
virological suppression despite suboptimal adherence could result
from host genetic and/or pharmacological factors. In fact, the
administration of standard doses of most antiretroviral drugs
results in a large inter-individual variability in plasma drug
concentrations [5,6]. The reasons for this variability are
multifactorial and may involve, besides adherence, factors such
as drug-drug interactions, co-morbidities, ethnicity or weight
differences, and genetics. In the recent years, genetic polymor-
phisms in genes coding for drug metabolizing enzymes or
transporters have been shown to influence the pharmacokinetics
of antiretroviral agents [7]. For instance, a correlation with
efavirenz disposition was demonstrated for a 516G.T polymor-
phism in CYP2B6 (CYP2B6*6). Individuals with the CYP2B6
516TT (homozygous loss of function) genotype had higher
efavirenz levels compared to carriers of 516GT (heterozygous loss
of function) or 516CC (homozygous reference) genotypes [8].
More recently, the contribution of CYP2B6 genetic variants to
efavirenz disposition was assessed in a pharmacogenetic- pharma-
cokinetic population analysis, and interestingly, explained half of
the inter-individual variability observed with this drug [9]. All
together, these factors could explain that some individuals may
have higher drug concentrations and may be able to maintain
effective levels even after missing doses. Intrinsic drug character-
istics such as half-life (long half-life) or drug potency are additional
factors that may also contribute to a continuous drug pressure
despite suboptimal adherence.
We used the longitudinal nature of the Swiss HIV Cohort Study
(SHCS) to select individuals with long periods of self-reported poor
adherence to HIV therapy and to investigate the genetic and
pharmacological characteristics in those remaining suppressed
compared to those not suppressed.
Methods
Participants
This study included HIV-infected patients enrolled in the
SHCS, a nationwide prospective cohort study enrolling HIV-
infected individuals aged 18 years or older who are followed-up in
HIV clinics (www.SHCS.ch) [10]. Eligible patients were Cauca-
sians, reported poor adherence on at least 2 consecutive follow-up
visits more than 3 months apart between January 2003 until May
2009, had at least 2 HIV-1 RNA values during the study period,
and were on regimens containing efavirenz (EFV) and/or boosted
lopinavir (LPV/r) for more than 24 weeks (see figure 1). The study
period was defined for each participant as the first until the last
reported date of poor adherence. Participants involved in a drug
trial with planned treatment interruptions were not eligible for this
study.
Ethics statement
The ethics committees of all participating centers approved the
genetic project and the permission for genetic analyses was
approved by the Institutional Review Boards/Ethics committees of
the University Hospitals of Basel, Lausanne, Zurich, Bern,
Geneva, St Gallen and Lugano. The participants gave written
informed consent for genetic testing.
Genetic analyses
Genotyping of single nucleotide polymorphisms (SNPs) in
candidate genes previously reported to decrease EFV (rs3745274,
marker of CYP2B6*6; rs35303484, marker of CYP2B6*11 and
rs35979566, marker of CYP2B6*15) [9,11] and LPV/r clearance
(rs4149056, marker of SLCO1B1*5; rs6945984 in CYP3A and
rs717620 in ABCC2) [12] was performed using commercially
available TaqMan allelic discrimination assays (Applied Biosystems,
Foster City, California, USA).
For each drug, the influence of candidate alleles was tested both
independently and jointly in a genetic score. Scores for each SNP
were defined as 0=Hom-Ref (homozygous reference) allele,
1 =Het-LOF (heterozygous loss of function) allele or Hom-LOF
(homozygous loss of function) allele. For LPV/r, score groups were
subsequently classified as: ,2 LOF alleles or $2 LOF alleles for
the combination of the 3 SNPs as done previously [12].
Drug levels
EFV and LPV/r drug levels were measured during therapeu-
tic drug monitoring only in case of clinical indication and
therefore were either not available or regularly documented in
all patients. Due to the limited number of drug levels measured
within the poor adherence period, we considered all EFV or
LPV/r levels available in a given individual. Drug levels are
expected to be consistently higher in carriers of genetic variants
thus making extrapolation a reasonable approach. Drug levels
were quantified by liquid chromatography coupled to tandem
mass spectrometry in accordance with previously validated
methods [13,14].
Since plasma levels were measured at random time after last
dose intake, observed EFV and LPV/r concentrations were
categorized according to percentiles to allow for comparison
between individuals. Concentration-time percentile curves (10th,
25th, 50th, 75th and 90th percentiles) were derived using simulations
based on previously published population pharmacokinetic models
[12,15] and performed using NONMEM (version VI, Icon
Development Solutions, Ellicott City, Maryland, USA). For
individuals with multiple drug measurements, the average
percentile was calculated.
Adherence monitoring and definition
Adherence was measured by participants’ self-report of non-
adherence. During the SHCS follow-up visits, the participants were
systematically asked two questions on adherence by their clinicians:
(i) How often did you miss a dose of your medication in the last
month? Daily, more than once a week, once a week, once every two
weeks, once a month, never; and (ii) Did you miss more than one
dose in a row? Yes, no. In this study, poor adherence was defined as
reporting missing doses of medication either ‘‘daily’’, ‘‘more than
once a week’’, or ‘‘once a week’’ on at least two consecutive reports.
The poor adherence criteria were based on a previous analysis of
the SHCS that showed a significantly higher risk of virological
rebound in virally suppressed individuals reporting missing doses of
ART$once a week in the last month compared to individuals
reporting never missing a dose of ART [16].
Determinants of Viral Suppression in Poor Adherers
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29186
Outcome and covariate definitions
The primary endpoint of the study was virological suppression
defined as having all HIV-RNA,400 copies/ml during the study
period.
Covariates that were potential confounders of the relationship
between host genetic or pharmacological factors and viral
suppression were considered for inclusion in the analysis:
demographic-related factors (age, gender), patient-related factors
(body mass index, current intravenous drug use, co-infection with
hepatitis B or C as defined below), condition-related factors (time
living with HIV, time on ART, CD4 cell count), and treatment
related-factors (prior mono or dual therapy, prior exposure to
ART, duration of viral suppression prior to study period,
nucleoside backbone, co-medications).
Hepatitis B virus infection was considered active if HBs antigen
or HBV DNA were positive. Hepatitis C virus infection was
considered active if anti-HCV antibody and HCV RNA were
positive and healed if HCV serology was positive and HCV RNA
negative. Elevation of liver enzymes (alanine aminostransferase
(ALT), aspartate aminotransferase (AST), alkaline phosphatase
Figure 1. Selection of the study population.
doi:10.1371/journal.pone.0029186.g001
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(ALP)) were graded according to the AIDS adverse event grading
table.
Statistical methods
Logistic regression models were utilized to estimate the effect of
host genetic factors and drug levels on viral suppression. Potential
confounders of the relationship between host genetic and
pharmacological factors were considered for inclusion in the
multivariable model although the small sample size limited the
number of variables. All analyses were carried out separately for
EFV and LPV/r. Estimates of the association between the
predictors and outcome are presented with odds ratios (OR) and
95% confidence intervals (CI).
In sensitivity analyses, we also considered an alterna-
tive definition for viral suppression - all HIV-1 RNA,50
copies/ml.
Table 1. Baseline characteristics of the study population.*
Variable Efavirenz Lopinavir
N 37 69
Age – median (IQR) 44 (41–54) 42 (38–47)
Male gender - % 83.8 71.0
Risk group for HIV infection- %
Men having sex with men 40.5 18.8
Heterosexual 46.0 29.0
Injecting drug users 13.5 44.9
Other 0.0 7.3
Past or current IDU - % 16.2 49.3
BMI, kg/m2 – mean (SD) 23.2 (4.2) 21.9 (4.1)
Nucleoside backbone - %
AZT+3TC 54.1 18.8
TDF+3TC 16.2 5.8
TDF+FTC 5.4 5.8
DDI+3TC 5.4 2.9
ABC+TDF 2.7 7.3
ABC+3TC 2.7 4.3
ABC+DDI 0 7.3
DDI+d4T 0 7.3
DDI+TDF 0 7.3
d4T+TDF 0 4.3
Triple NRTI 0 13.0
Other 13.5 15.9
Prior mono or dual therapy - % 32.4 56.5
Prior exposure to NNRTI - % 46.0 21.7
Prior exposure to boosted PI - % 27.0 65.2
Number of previous regimens – median (IQR) 2 (0–4) 4 (1–8)
On co-medication - % 40.5 46.4
Hepatitis C !- % 18.9 52.9
Hepatitis B ! - % 5.6 6.2
Baseline CD4 cell count ,200 m/L - % 8.1 23.2
RNA 400 copies/ml " - % 75.7 55.1
Duration of suppression prior to baseline (months) – median (IQR) 21.2 (9.2–48.1) 13.9 (0–28.4)
Time on ART (years)
Median (IQR) 4.0 (1.1–7.8) 5.8 (2.5–8.2)
Time living with HIV (years)
Median (IQR) 8.7 (6.4–12.9) 13.4 (8.7–16.5)
*Baseline is the beginning of the poor adherence period which was defined as 2 consecutive self-reports of missed doses at least 1 per week over at least a 12 week
period.
!See Methods section for definition.
"Patients suppressed on the current regimen at baseline and throughout the study period.
IQR = interquartile range, SD= standard deviation, BMI = body max index, IDU = injecting drug use.
3TC = lamivudine, ABC = abacavir, AZT = zidovudine, d4T = stavudine, DDI = didanosine, FTC = emtricitabine, TDF = tenofovir.
doi:10.1371/journal.pone.0029186.t001
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All analyses were done with SAS v 9.2 (SAS Institute, Cary,
North Carolina) and Stata 10.1 (StataCorp, College Station,
Texas).
Results
Study population
Over the 6.5 year study period, 648 poor adherence periods
from 542 individuals were recorded. The patient selection process
is depicted in Figure 1. In the end, 37 individuals on EFV and 69
on LPV/r were included. The median length of poor adherence
in both groups was 32 weeks with 18.9% of EFV and 20.3% of
LPV/r patients indicating they missed a dose of ART on a daily
basis. Demographics of the two populations are described in
Table 1.
In the EFV group, 28/37 (75.7%) maintained a viral load ,400
copies/ml throughout the period of poor adherence. In the LPV
group, only 38/69 (55.1%) of patients remained suppressed
throughout the study period.
Effect of genetic factors on viral suppression
In the group of patients receiving EFV, genetic variants were
found in CYP2B6 only for rs3745274 with an allele frequency of
25%. In the group of patients receiving LPV/r, genetic variants
were found in SLCO1B1 (rs4149056), CYP3A (rs6945984) and
ABCC2 (rs717620) with allele frequencies of 19%, 9% and 22%,
respectively (Table 2). Overall, the observed allele frequencies
were in good agreement with publicly available SNPs database
(www.ncbi.nlm.nih.gov/SNP).
Univariable and multivariable logistic regression analyses for
EFV failed to detect an association between 516G.T polymor-
phism in CYP2B6 and the likelihood of remaining suppressed
(Table 3).
Univariable and multivariable logistic regression analyses for
LPV/r failed to detect an association between each independent
SNP and viral suppression (p.0.15) with the exception of the
univariable result for SLCO1B1*5 (OR 0.37, 95% CI: 0.13–1.06,
p = 0.06). When analyzing the joint effect of the 3 SNPs in a
Table 2. Adherence, pharmacokinetic, and genetic information.
Variable Efavirenz Lopinavir/r
N 37 69
Number of completed adherence questionnaires 2 (2–3) 2 (2–4)
Median (IQR)
Worst reported missed doses - %
1 time per week 43.2 29.0
.1 time per week 37.8 50.7
Daily 18.9 20.3
Missed .1 dose in a row in past 4 weeks - % 62.6 56.5
Length of poor adherence period (weeks)
Median (IQR) 32.0 (27.7–61.0) 32.1 (22.1–58.6)
Drug level ! - percentile value
Median (IQR) 34.3 (22.5–60.0) 53.8 (32.5–70.0)
Genetic polymorphism {- %
CYP2B6*6 (rs3745274)
Hom-Ref 53.1 NA
Het-LOF 43.8 NA
Hom-LOF 3.1 NA
SLC01B1*5 (rs4149056)
Hom-Ref NA 64.1
Het-LOF NA 34.4
Hom-LOF NA 1.6
CYP3A (rs6945984)
Hom-Ref NA 81.2
Het-LOF NA 18.8
Hom-LOF NA 0
ABCC2 (rs717620)
Hom-Ref NA 59.4
Het-LOF NA 37.5
Hom-LOF NA 3.1
!Average percentile values were used when multiple drug measurements were performed in a single patient. Drug levels available in 30% of participants on EFV and
50% of those on LPV/r treatment.
{EFV: Genetic results available in 86% of patients for the allele CYP2B6*6; No study participants carried a loss/diminished-function CYP2B6*11 or *15 alleles; LPV: Genetic
results available in 93% of patients.
IQR = interquartile range, Het = heterozygous, Hom=homozygous, LOF = loss of function, Ref = reference allele. NA= not applicable.
doi:10.1371/journal.pone.0029186.t002
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genetic score, the univariable logistic regression showed a trend
between a decreased likelihood of viral suppression in carriers of
genetic variations (p = 0.08) however the trend did not remain in
the multivariable analysis.
Effect of drug levels on viral suppression
Drug concentrations were only available in 30% of EFV and
50% of LPV/r patients. For most patients, the intra-individual
variability in drug levels was very pronounced further supporting
the poor adherence pattern in this selected population. No
association were found between higher drug levels (expressed as
average percentile value) and presence of genetic variants in EFV
patients (p = 0.36) or combined genetic variants in LPV/r patients
(p = 0.26). The analysis of independent genetic variants in LPV/r
patients showed a correlation between carriers of SLCO1B1*5 and
higher drug levels (average percentile value in carriers vs non
carriers: 62 vs 42, p = 0.03) but not for carriers of variants in
CYP3A (p = 0.63) and ABCC2 (p = 0.61).
No association was found between higher drug levels and the
likelihood of remaining suppressed in EFV (p= 0.54) and LPV/r
patients (p = 0.12). However, single or repetitive exposure to low
drug levels (i.e. #10th percentile) was associated with a lower
likelihood of viral suppression in LPV/r patients (OR 4.40, 95%
CI: 1.04–18.60, p = 0.04). Due to the small number of patients
with available drug concentrations, drug levels were not included
in the multivariable analyses.
Effect of adherence on viral suppression
Despite all patients having reported poor adherence, differences
in the likelihood of viral suppression could still be seen between the
adherence levels (Tables 3 and 4). Individuals on LPV/r missing
.1 dose per week were significantly less likely to experience viral
suppression than those missing 1 dose a week (OR 0.06, 95% CI:
0.01–0.55, p= 0.01). For EFV patients, a similar trend was found
but this was not statistically significant (OR 0.11, 95% CI: 0.01–
2.03, p = 0.14).
Predictors of virological suppression
In univariable models of EFV patients, only low adherence was
significantly associated with decreased odds of viral suppression
Table 3. Logistic regression models for sustained viral suppression (RNA,400 copies/ml) during poor adherence period for those
on EFV.
Variable
Univariable
OR (95% CI)
Multivariable
OR (95% CI)
Mult.
p-value
CYP2B6 { 1.67 (0.32–8.59) 3.25 (0.10–106.82) 0.51
Low adherence " 0.11 (0.01–0.99) 0.11 (0.01–2.03) 0.14
Prior suppression on current ART 3.40 (0.62–18.75) 4.07 (0.36–46.26) 0.26
Prior exposure to NNRTI regimen 0.60 (0.13–2.72) 0.59 (0.04–7.65) 0.68
Length of poor adherence period (weeks) 1.01 (0.98–1.04) 1.03 (0.94–1.13) 0.57
Time since HIV diagnosis (per 5 years) 0.58 (0.29–1.19) 0.38 (0.09–1.61) 0.19
{Reference group for analyses is those with reference allele. Genetic results available in 86% of patients for the allele CYP2B6*6; No study participants carried a loss/
diminished-function CYP2B6*11 or CYP2B6*15 alleles.
"Low adherence is defined as missing doses of ART more than 1 time per week. Reference group is those who missed a dose of ART 1 time per week.
doi:10.1371/journal.pone.0029186.t003
Table 4. Logistic regression models for sustained viral suppression (RNA,400 copies/ml) during poor adherence period for those
on LPV.
Variable
Univariable
OR (95% CI)
Multivariable
OR (95% CI)
Mult.
p-value
Combined variants: $2 LOF alleles { 0.38 (0.13–1.11) 0.59 (0.06–5.52) 0.64
Low adherence " 0.29 (0.09–0.94) 0.06 (0.01–0.55) 0.01
Prior suppression on current ART 5.65 (1.82–17.56) 8.74 (1.03–74.18) 0.05
Prior exposure to boosted PI 0.48 (0.17–1.34) 0.16 (0.01–1.79) 0.14
Length of poor adherence period (weeks) 1.00 (0.98–1.02) 1.02 (0.99–1.05) 0.26
Age (years) 1.03 (0.98–1.09) 1.20 (1.01–1.41) 0.04
Past or current IDU 0.37 (0.14–0.98) 0.52 (0.09–3.20) 0.48
Taking co medication# 0.33 (0.12–0.88) 0.55 (0.04–7.36) 0.65
CD4 cell count $200 m/L 3.63 (1.10–11.98) 1.75 (0.16–19.38) 0.65
Mild elevation of ALP 0.29 (0.10–0.87) 0.22 (0.03–1.69) 0.15
Time since HIV diagnosis (per 5 years) 0.49 (0.29–0.83) 0.47 (0.17–1.29) 0.14
{Reference group for analyses is those with reference allele or one variant for the combination of the 3 genetic variants. Genetic results available in 93% of patients.
"Low adherence is defined as missing doses of ART more than 1 time per week. Reference group is those who missed a dose of ART 1 time per week.
#Taking any co medication for longer than 30 days during the study period.
ALP = alkaline phosphatase, IDU = injecting drug use, LOF = loss of function.
doi:10.1371/journal.pone.0029186.t004
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(p = 0.05) (Table 3). However, in multivariable models, the effect
was attenuated and was no longer significant (p = 0.14).
In univariable models of LPV/r patients, having low adherence
levels, past or current IDU, co-medication, mild elevation of ALP
(.1.25–2.5 above the upper limit of normal), or longer time since
HIV diagnosis was significantly correlated with a decreased
likelihood of remaining suppressed during the period of poor
adherence. Prior suppression on the current regimen and higher
baseline CD4 cell count were associated with an increased
likelihood of remaining suppressed despite poor adherence
(Table 4). In multivariable models, only low adherence and prior
suppression remained significant whereas older age was associated
with an increased likelihood of remaining suppressed.
These findings remained consistent when defining viral
suppression as RNA,50 copies/ml.
Discussion
Nearly perfect adherence to antiretroviral therapy is widely
accepted as the primary determinant for achieving and maintain-
ing viral response. However, less is known about the determinants
of virological suppression observed paradoxically in some
individuals with long periods of self-reported poor adherence to
ART. We hypothesized that individuals carrying genetic variants
associated with a slow metabolizing profile would maintain
sufficient viral inhibitory drug levels even after missing doses.
In our study population, we failed to show a correlation between
516G.T polymorphism in CYP2B6 and the likelihood of
remaining suppressed in patients with self-reported suboptimal
adherence to EFV based regimens. The population pharmacoki-
netic estimates of EFV half-lives have been reported to be 23, 27
and 48 hours for individuals with the CYP2B6 516 GG, GT and
TT genotypes, respectively [17]. Our study population was mainly
characterized by carriers of the CYP2B6 516 GG (53%) and 516
GT genotypes (44%) whereas only one patient had the 516 TT
genotype (Table 2). Thus, our results suggest that the modest
increase in EFV half-life (17%) associated with the CYP2B6 516
GT genotype might not be strong enough to compensate for
inconsistent adherence by maintaining effective levels until the
subsequent dose.
In the multivariable analyses, no correlation was found between
independent or combined genetic variants and the likelihood of
remaining suppressed in patients with suboptimal adherence to
LPV/r based regimens. Although there was a trend to increased
drug levels with the SLCO1B1*5 allele, this did not translate in
protection from virological failure. One should note that while the
genetic determinants of EFV blood levels are well understood [9]),
the contribution of genetics to the inter-individual variability of
LPV/r pharmacokinetics is modest (less than 5%) [12].
In our population, the likelihood of remaining suppressed was
rather related to the degree of adherence. The estimated minimal
level of adherence to maintain viral suppression was 86% for EFV
and 93% for LPV/r (mainly administered twice daily in our
population) as indicated by the increased risk of viral failure in
patients missing more than 1 dose a week compared to those
missing 1 dose a week (Tables 3 and 4). The lower adherence
threshold required for EFV compared to LPV/r was supported by
the difference in observed rate of viral suppression in that 76% of
the patients receiving EFV versus 55% treated with LPV/r
remained suppressed throughout the study period. Our results are
consistent with previous studies showing that viral suppression can
be reached in some but not all patients at a level of adherence
averaging 80% for NNRTI-based regimens [3,4,18,19] and
.90% for PI-based regimens [2,3,4,18,20]. The higher adherence
threshold observed in our study might reflect the fact that we used
self-reported adherence, which overestimates adherence by 10–
20% compared to electronic monitoring [21,22]. In our study, the
degree of adherence rather than consecutive missed doses was a
stronger predictor for viral suppression in EFV and LPV/r
models. EFV forgiveness of non-adherence has been reported to
be likely attributable to its extended half-life [3,4,19], whereas
LPV/r has a high genetic barrier to resistance which may enhance
its forgiveness [23,24].
Besides the degree of adherence, we found that the likelihood of
remaining suppressed was also dependent on the dosing schedule
for LPV/r. In our population, LPV/r was administered twice daily
(BID) in 64 patients and once daily (QD) in 5 patients.
Interestingly, the failure rate was higher in those on a QD
regimen with 80% (4/5) of the patients on the LPV/r QD regimen
compared to 42% (27/64) on the LPV/r BID regimen not
maintaining viral suppression. This observation is compatible with
the findings of a recent study comparing the pharmacokinetics of
LPV/r BID and QD following drug cessation [25]. Although no
participants receiving LPV/r BID had drug levels below the
minimal effective concentration (MEC) at 12 hours, 44% of
participants receiving LPV/r QD were below the MEC at
24 hours. The higher occurrence of virological failure observed
in some clinical trials with the LPV/r QD regimen seems to be
related to the fast decay of LPV/r and the achievement of sub-
therapeutic concentrations [25].
Interestingly, our data showed that the probability of
remaining suppressed increased with the duration of continuous
suppression prior to the poor adherence period in both groups,
which is in agreement with previous data [26,27]. It has been
postulated that initial treatment during high viral burden likely
required higher levels of adherence for full viral suppression than
later in chronic treatment when viral burden was less [26,27].
Furthermore, it has been reported that the latent reservoir and its
ability to reactivate upon stimulation with cognate antigen
decreases with duration of treatment [28]. Thus, individuals may
be more vulnerable to suboptimal adherence shortly after
achieving viral suppression but may be able to tolerate missed
doses after long-term viral suppression. It should be noted that
the probability of remaining suppressed might also be related to
inter-individual differences in immune response to HIV virus.
Factors such as thymus output, co-infections, residual viral
production, age, gender, genetics of immune system, nadir of
CD4 cell are known to impact the immune response to HIV [29].
This assumption is supported by the observation that in the
univariable model of LPV/r patients, higher baseline CD4 cell
count was associated with an increased likelihood of remaining
suppressed.
Limitations
Some limitations of our study should be acknowledged. The
stringent selection criteria of our study population (severe non
adherence and being steadily on EFV and/or LPV/r) gave us a
small sample size and limited power to explore associations in our
data. In addition, the limited number of patients with documented
drug levels did not allow satisfactory exploration of the role of drug
concentration as a predictor of viral suppression. Although, due to
the high level of non-adherence, this relationship may have been
difficult to quantify precisely.
Conclusions
The investigated genetic variants did not play a significant role
in the sustained viral suppression of individuals with poor
adherence. The risk of virological failure decreased with longer
Determinants of Viral Suppression in Poor Adherers
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duration of viral suppression in this selected population. Patients
varied considerably in their prior ART exposure and, although we
attempted to adjust for this and the possibility of resistance, we
cannot exclude the potential impact of these factors.
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